Logo

American Heart Association

  26
  0


Final ID: Sa2066

Yentl Syndrome Refuted: Cholesterol Management from a Multicenter Healthcare System

Abstract Body (Do not enter title and authors here): Background: According to the GOULD registry, the median low-density lipoprotein (LDL) after coronary revascularization is 99mg/dL. Similarly, a large-scale New York City health system cohort (2018-2023) reports 52% of those who underwent revascularization had a median follow-up LDL<70 mg/dL. Our retrospective study assesses the current practices of cholesterol-lowering therapy and secondary risk reduction strategies for patients who have undergone percutaneous intervention (PCI) or coronary artery bypass grafting (CABG) from September 2011 to September 2023. The study spans all 25 Advocate Aurora Health medical centers in Wisconsin and Illinois.

Methods: Among the 42,561 identified patients, 20,501 were excluded because of incomplete data. The primary outcome was LDL characteristics after revascularization in male (Group A) and female (Group B) cohorts. Secondary analysis included patient demographics, medical conditions associated with increased cardiovascular risk, and prevalence of non-statin therapy usage. The Chi-square test or Fisher’s exact test was used to compare the groups for categorical variables, and the Wilcoxon Rank Sum test was used to compare the groups for numerical variables. Confidence intervals (95%) were also used with the descriptive statistics to describe the characteristics of the cohorts.

Results: Eligible for the study were 15,311 males with a median age of 68 years old and 6,749 females with a median age of 70 years old. A majority of individuals were White (80%) and had a BMI >29 across both groups. Compared with their male counterparts, a heightened prevalence of cardiovascular risk factors was identified amongst the women, including history of myocardial infarction, congestive heart failure, diabetes, hypertension, stroke, peripheral arterial disease, chronic obstructive pulmonary disease, and chronic kidney disease. Key risk factors more prevalent in men included atrial fibrillation and cancer. Both groups had 95% statin utilization after coronary revascularization and achieved post-revascularization LDL levels of 61mg/dL and 67 mg/dL in males and females, respectively.

Conclusion: The study’s findings suggest that healthcare systems can successfully implement secondary prevention strategies to achieve LDL levels <70 after coronary revascularization for both male and female patients at very high risk of developing future cardiovascular events.
  • Koza, Anya  ( Aurora St. Luke’s/Sinai Medical Centers, Aurora Health Care , Milwaukee , Wisconsin , United States )
  • Gogineni, Venkateswara  ( Aurora Sinai/Aurora St. Luke's Medical Centers, Aurora Health Care , Milwaukee , Wisconsin , United States )
  • Bajwa, Tanvir  ( Aurora Sinai/Aurora St. Luke's Medical Centers, Aurora Health Care , Milwaukee , Wisconsin , United States )
  • Allaqaband, Suhail  ( Aurora Sinai/Aurora St. Luke's Medical Centers, Aurora Health Care , Milwaukee , Wisconsin , United States )
  • Boulware, David  ( Aurora Sinai/Aurora St. Luke's Medical Centers, Aurora Health Care , Milwaukee , Wisconsin , United States )
  • Jan, M. Fuad  ( Aurora Sinai/Aurora St. Luke's Medical Centers, Aurora Health Care , Milwaukee , Wisconsin , United States )
  • Author Disclosures:
    Anya Koza: DO NOT have relevant financial relationships | Venkateswara Gogineni: DO NOT have relevant financial relationships | Tanvir Bajwa: DO have relevant financial relationships ; Speaker:Medtronic:Active (exists now) ; Other (please indicate in the box next to the company name):Honoraria, Medtronic:Active (exists now) ; Consultant:Medtronic:Active (exists now) | Suhail Allaqaband: DO have relevant financial relationships ; Consultant:Medtronic:Active (exists now) ; Individual Stocks/Stock Options:Medtronic:Active (exists now) ; Individual Stocks/Stock Options:Edwards Lifesciences:Active (exists now) ; Individual Stocks/Stock Options:Boston Scientific:Active (exists now) ; Consultant:Boston Scientific:Active (exists now) ; Consultant:GE Healthcare:Active (exists now) ; Other (please indicate in the box next to the company name):Proctor for Medtronic:Active (exists now) | David Boulware: DO NOT have relevant financial relationships | M. Fuad Jan: DO NOT have relevant financial relationships
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

Cardiometabolic Crossroads: Innovations and Insights in Lipids, Diabetes, and Cardiovascular Outcomes

Saturday, 11/08/2025 , 10:30AM - 11:30AM

Abstract Poster Board Session

More abstracts on this topic:
A 3-Year, Pre-Trial, Real-world Data Analysis of Patients Enrolled in VICTORION-INITIATE: Insights Using Tokenization

Rodriguez Fatima, Cosmatos Irene, Desai Nihar, Wright R, Ross Elsie, Ali Yousuf, Kumar Biswajit, Han Guangyang, Cai Beilei, Abbas Cheryl, Ryan Amy

An Economic Evaluation of Non-HDL-Cholesterol and Apolipoprotein B as Treatment Targets for Lipid-Lowering Therapy in Primary Prevention

Luebbe Samuel, Wilkins John, Moran Andrew, Sniderman Allan, Kohli-lynch Ciaran

More abstracts from these authors:
Secular Trends and Mortality Rates in Percutaneous Coronary Intervention in Non-ST Elevation Acute Coronary Syndrome: 15-Year Nationwide Survey

Abood Zaid, Allaqaband Suhail, Sokhal Balamrit, Tunink Kirsten, Hommeida Mohamed, Bajwa Tanvir, Jan M. Fuad

Inpatient Mortality Trend in Obese Versus Non-Obese Patients With Acute Coronary Syndrome: “An Obesity Paradox” – 15-Year Nationwide Sample Analysis

Abood Zaid, Bajwa Tanvir, Sokhal Balamrit, Tunink Kirsten, Hommeida Mohamed, Allaqaband Suhail, Jan M. Fuad

You have to be authorized to contact abstract author. Please, Login
Not Available